Pfizer Czech Republic made a net profit of CZK CZK 103 mil under revenues of CZK 3,586 mil in 2017, up 39.7% and 10.6%, respectively, when compared to the last year.
This translates into a net margin of 2.86%. Historically, the firm’s net margin reached an all time high of 7.17% in 2003 and an all time low of -30.0% in 2002. The average net margin in the last five years amounted to 2.58%.
On the operating level, EBITDA margin reached 3.68% and EBIT amounted to 4.36% of sales in 2017.
As far as Pfizer Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.
You can see all the company’s data at Pfizer Czech Republic Profile, or you can download a report on the company in the report section.
Net Margin | Unit | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
Amgen Czech Republic | % | 10.9% | 6.81% | 6.14% | 6.36% | 5.93% | |||
Bayer Czech Republic | % | 4.96% | 2.57% | 2.80% | 2.64% | 2.89% | |||
GlaxoSmithKline Czech Republic | % | 4.12% | 2.86% | 2.25% | 1.81% | 2.85% | |||
Merck Czech Republic | % | 3.04% | 3.62% | 1.59% | 1.94% | 3.71% | |||
Novartis Czech Republic | % | 1.05% | 1.27% | 1.29% | 1.75% | 1.53% | |||
Pfizer Czech Republic | % | 3.40% | 1.54% | 2.67% | 2.70% | 2.41% | |||
Roche Czech Republic | % | 1.01% | 0.794% | 2.73% | 2.17% | 0.936% | ... | ||
Sanofi-Aventis Czech Republic | % | 0.782% | 0.626% | 0.998% | 0.019% | 0.889% | |||
Servier Czech Republic | % | ... | ... | 3.85% | 3.94% | 3.09% | 2.41% | ||
Walmark | % | 9.83% | -0.140% | -0.444% | 1.82% | -58.0% | |||
AVERAGE | % | 2.88% | 4.35% | 2.38% | 2.40% | 2.43% | -3.45% | 1.06% | 3.38% |